Kalshi and Polymarket permit bets on clinical trial results and FDA drug approvals. Researchers have raised concerns about potential insider trading and interference with trial integrity. A family case involving a 12-year-old cancer patient illustrates the personal stakes referenced in coverage.
“Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'”
Read at NPR →No center sources covered this
No right-leaning sources covered this
Markets extend financial speculation into healthcare, risking commodification of suffering and erosion of trust in medical research.
“Profit motives overriding patient safeguards and inequality from information asymmetries”
Markets aggregate information on drug viability and regulatory performance through voluntary exchange.
“Empirical forecasting benefits over regulatory prohibition based on sentiment”
Adults should freely contract on public outcomes without state interference beyond fraud rules.
“Individual liberty in risk allocation and dispersed knowledge surfacing”
All views accept an emotional narrative hook without testing whether claimed risks have materialized or whether indirect pricing already exists.
“Unexamined assumptions about liquidity, CFTC oversight, and biotech equity channels”
Ratings by MBFC